Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;105:2497-2503
Published online before print May 6, 2002, doi: 10.1161/01.CIR.0000017187.61348.95
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
105/21/2497    most recent
01.CIR.0000017187.61348.95v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gong, H.
Right arrow Articles by Harding, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gong, H.
Right arrow Articles by Harding, S. E.
Related Collections
Right arrow Animal models of human disease
Right arrow Cell signalling/signal transduction
Right arrow Genetically altered mice
Right arrow Heart failure - basic studies
Right arrow Receptor pharmacology

(Circulation. 2002;105:2497.)
© 2002 American Heart Association, Inc.


Clinical Investigation and Reports

Specific ß2AR Blocker ICI 118,551 Actively Decreases Contraction Through a Gi-Coupled Form of the ß2AR in Myocytes From Failing Human Heart

Haibin Gong, PhD; Hong Sun, MD; Walter J. Koch, PhD; Thomas Rau, MD; Thomas Eschenhagen, PhD; Ursula Ravens, PhD; Jürgen F. Heubach, PhD; Dawn L. Adamson, MB, BS; Sian E. Harding, PhD

From the National Heart and Lung Institute, Imperial College School of Medicine, London, UK; Department of Experimental Surgery (W.J.K.), Duke University Medical Center, Durham, NC; Institute of Pharmacology (T.R., T.E.), University of Erlangen, Germany; and Institut fur Pharmakologie und Toxikologie (U.R., J.F.H.), Universitat Carl Gustav Carus, Dresden, Germany.

Correspondence to Dr Sian E. Harding, National Heart and Lung Institute, Faculty of Medicine, Imperial College School of Science, Technology and Medicine, Dovehouse St, London SW3 6LY, UK. E-mail sian.harding{at}ic.ac.uk

Background We have observed direct (noncatecholamine-blocking) negative inotropic effects of the selective ß2-adrenoceptor (AR) antagonist ICI 118,551 in myocytes from failing human ventricle. In this study we characterize the effect in parallel in human myocytes and in myocytes from animal models where ß2ARs or Gi proteins are overexpressed.

Methods and Results Enzymatically isolated, superfused ventricular myocytes were exposed to ßAR agonists and antagonists/inverse agonists, and contraction amplitude was measured. ICI 118,551 decreased contraction in ventricular myocytes from failing human hearts by 45.3±4.1% (n=20 hearts/31 myocytes, P<0.001) but had little effect in nonfailing hearts (4.9±4%, n=5 myocytes/3 hearts). Effects were significantly larger in patients classified as end-stage. Transgenic mice with high ß2AR number and increased Gi levels had normal basal contractility but showed a similar negative inotropic response to ICI 118,551. Overexpression of human ß2AR in rabbit myocytes using adenovirus potentiated the negative inotropic effect of ICI 118,551. In human, rabbit, and mouse myocytes, the negative inotropic effects were blocked after treatment of cells with pertussis toxin to inactivate Gi, and overexpression of Gi{alpha}2 induced the effect de novo in normal rat myocytes.

Conclusions We hypothesize that ICI 118,551 binding directs the ß2AR to a Gi-coupled form and away from the Gs-coupled form (ligand-directed trafficking). ICI 118,551 effectively acts as an agonist at the Gi-coupled ß2AR, producing a direct negative inotropic effect. Conditions where ß2ARs are present and Gi is raised (failing human heart, TGß2 mouse heart) predispose to the appearance of the negative inotropic effect.


Key Words: myocytes • receptors, adrenergic, beta • contractility • heart failure




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
A. R. Lyon, K. T. MacLeod, Y. Zhang, E. Garcia, G. K. Kanda, M. J. Lab, Y. E. Korchev, S. E. Harding, and J. Gorelik
Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart
PNAS, April 21, 2009; 106(16): 6854 - 6859.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
U. Siedlecka, M. Arora, T. Kolettis, G. K. R. Soppa, J. Lee, M. A. Stagg, S. E. Harding, M. H. Yacoub, and C. M. N. Terracciano
Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes
Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H1917 - H1926.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. Ding, R. F. Wiegerinck, M. Shen, A. Cojoc, C. M. Zeidenweber, and M. B. Wagner
Dopamine increases L-type calcium current more in newborn than adult rabbit cardiomyocytes via D1 and {beta}2 receptors
Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2327 - H2335.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. Muthumala, F. Drenos, P. M. Elliott, and S. E. Humphries
Role of {beta} adrenergic receptor polymorphisms in heart failure: Systematic review and meta-analysis
Eur J Heart Fail, January 1, 2008; 10(1): 3 - 13.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. P. Collis, S. Srivastava, W. A. Coetzee, and M. Artman
beta2-Adrenergic receptor agonists stimulate L-type calcium current independent of PKA in newborn rabbit ventricular myocytes
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2826 - H2835.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X.-H. Zhang, G.-R. Li, and J.-P. Bourreau
The effect of adrenomedullin on the L-type calcium current in myocytes from septic shock rats: signaling pathway
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2888 - H2893.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
V. O. Nikolaev, M. Bunemann, E. Schmitteckert, M. J. Lohse, and S. Engelhardt
Cyclic AMP Imaging in Adult Cardiac Myocytes Reveals Far-Reaching {beta}1-Adrenergic but Locally Confined {beta}2-Adrenergic Receptor-Mediated Signaling
Circ. Res., November 10, 2006; 99(10): 1084 - 1091.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. J. Birks, P. D. Tansley, J. Hardy, R. S. George, C. T. Bowles, M. Burke, N. R. Banner, A. Khaghani, and M. H. Yacoub
Left Ventricular Assist Device and Drug Therapy for the Reversal of Heart Failure
N. Engl. J. Med., November 2, 2006; 355(18): 1873 - 1884.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Mittra and J.-P. Bourreau
Gs and Gi coupling of adrenomedullin in adult rat ventricular myocytes
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1842 - H1847.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. Metra, C. Torp-Pedersen, K. Swedberg, J. G.F. Cleland, A. Di Lenarda, M. Komajda, W. J. Remme, B. Lutiger, A. Scherhag, M. A. Lukas, et al.
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
Eur. Heart J., November 1, 2005; 26(21): 2259 - 2268.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Maudsley, B. Martin, and L. M. Luttrell
The Origins of Diversity and Specificity in G Protein-Coupled Receptor Signaling
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 485 - 494.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Maudsley, L. Davidson, A. J. Pawson, R. Chan, R. L. de Maturana, and R. P. Millar
Gonadotropin-Releasing Hormone (GnRH) Antagonists Promote Proapoptotic Signaling in Peripheral Reproductive Tumor Cells by Activating a G{alpha}i-Coupling State of the Type I GnRH Receptor
Cancer Res., October 15, 2004; 64(20): 7533 - 7544.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Pepe, O. W.V van den Brink, E. G Lakatta, and R.-P. Xiao
Cross-talk of opioid peptide receptor and {beta}-adrenergic receptor signalling in the heart
Cardiovasc Res, August 15, 2004; 63(3): 414 - 422.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
M. Zaugg and M. C. Schaub
Cellular mechanisms in sympatho-modulation of the heart
Br. J. Anaesth., July 1, 2004; 93(1): 34 - 52.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. El-Armouche, O. Zolk, T. Rau, and T. Eschenhagen
Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure
Cardiovasc Res, December 1, 2003; 60(3): 478 - 487.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. Chakir, Y. Xiang, D. Yang, S.-J. Zhang, H. Cheng, B. K. Kobilka, and R.-P. Xiao
The Third Intracellular Loop and the Carboxyl Terminus of {beta}2-Adrenergic Receptor Confer Spontaneous Activity of the Receptor
Mol. Pharmacol., November 1, 2003; 64(5): 1048 - 1058.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R.-P. Xiao, S.-J. Zhang, K. Chakir, P. Avdonin, W. Zhu, R. A. Bond, C. W. Balke, E. G. Lakatta, and H. Cheng
Enhanced Gi Signaling Selectively Negates {beta}2-Adrenergic Receptor (AR)- but Not {beta}1-AR-Mediated Positive Inotropic Effect in Myocytes From Failing Rat Hearts
Circulation, September 30, 2003; 108(13): 1633 - 1639.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-C. Peter, P. Eftekhari, P. Billiald, G. Wallukat, and J. Hoebeke
scFv Single Chain Antibody Variable Fragment as Inverse Agonist of the {beta}2-Adrenergic Receptor
J. Biol. Chem., September 19, 2003; 278(38): 36740 - 36747.
[Abstract] [Full Text] [PDF]